Heparin Dosing in 86-Year-Old NSTEMI Patient
For an 86-year-old patient with NSTEMI, unfractionated heparin (UFH) should be dosed as an initial IV bolus of 60 IU/kg (maximum 4000 IU) followed by continuous IV infusion at 12 IU/kg/hour (maximum 1000 IU/hour), adjusted to maintain aPTT 1.5-2 times control, continued for 48 hours or until PCI is performed 1, 2.
Rationale for Continuous IV Infusion (Not BD or TDS Subcutaneous)
The question asks about "BD or TDS" (twice or three times daily) dosing, which typically refers to subcutaneous administration. However, current guidelines do not recommend subcutaneous UFH for acute NSTEMI treatment—this route is reserved for VTE prophylaxis, not acute coronary syndrome management.
For therapeutic anticoagulation in NSTEMI:
- Continuous IV infusion is the standard of care for UFH in NSTEMI 1, 2
- The 2014 AHA/ACC guidelines explicitly recommend: "UFH IV: initial loading dose of 60 IU/kg (maximum 4000 IU) with initial infusion of 12 IU/kg per hour (maximum 1000 IU/h) adjusted per activated partial thromboplastin time" 1
- This regimen provides stable, predictable anticoagulation with ability to monitor and adjust dosing
Age-Specific Considerations for This 86-Year-Old Patient
Critical caveat: Elderly patients over 60 years may require lower heparin doses 3. The FDA labeling specifically states "Patients over 60 years of age may require lower doses of heparin" 3.
Practical dosing approach:
- Start with weight-adjusted dosing (60 IU/kg bolus, 12 IU/kg/hour infusion)
- Monitor aPTT closely (every 4 hours initially) 3
- Be prepared to reduce infusion rate if aPTT exceeds target (1.5-2 times control)
- Higher bleeding risk in elderly: Watch for major bleeding complications
Alternative: Enoxaparin (Preferred in This Age Group)
Consider enoxaparin 1 mg/kg SC every 12 hours as a superior alternative 1, 2:
- Dose adjustment required: In patients ≥75 years with CrCl <30 mL/min, reduce to 1 mg/kg SC once daily 1
- More predictable anticoagulation without monitoring
- Superior efficacy compared to UFH in NSTEMI 4, 5
- Calculate creatinine clearance before initiating—essential in 86-year-old patients 1
The 2014 guidelines note: "In the presence of impaired renal function (CrCl <30 mL per minute), which is a common finding in older patients, the dose should be reduced to 1 mg/kg SC once daily, and strong consideration should be given to UFH as an alternative" 1.
Monitoring and Duration
- UFH: Check aPTT every 4 hours initially, then at appropriate intervals once stable 3
- Duration: Continue anticoagulation for 48 hours or until PCI is performed 1, 2
- Discontinue after uncomplicated PCI 6
- Monitor platelet counts, hematocrit, and occult blood throughout therapy 3
Key Pitfalls to Avoid
- Do NOT use subcutaneous UFH BD or TDS for acute NSTEMI—this is prophylactic dosing, not therapeutic
- Do NOT use standard fixed doses in elderly patients—weight-adjusted dosing with lower maximums is essential 7
- Do NOT forget renal function assessment before choosing enoxaparin in an 86-year-old 1
- Excess dosing is common in elderly and low-weight patients, leading to increased bleeding 7